GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » EV-to-FCF

ValiRx (LSE:VAL) EV-to-FCF : -1.40 (As of Apr. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ValiRx's Enterprise Value is £3.70 Mil. ValiRx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.64 Mil. Therefore, ValiRx's EV-to-FCF for today is -1.40.

The historical rank and industry rank for ValiRx's EV-to-FCF or its related term are showing as below:

LSE:VAL' s EV-to-FCF Range Over the Past 10 Years
Min: -4.01   Med: -0.06   Max: 0.05
Current: -1.4

During the past 13 years, the highest EV-to-FCF of ValiRx was 0.05. The lowest was -4.01. And the median was -0.06.

LSE:VAL's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.27 vs LSE:VAL: -1.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), ValiRx's stock price is £0.0345. ValiRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.025. Therefore, ValiRx's PE Ratio for today is At Loss.


ValiRx EV-to-FCF Historical Data

The historical data trend for ValiRx's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx EV-to-FCF Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -0.96 -5.35 -18.13 -6.60

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -18.13 - -6.60 -

Competitive Comparison of ValiRx's EV-to-FCF

For the Biotechnology subindustry, ValiRx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ValiRx's EV-to-FCF falls into.



ValiRx EV-to-FCF Calculation

ValiRx's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3.704/-2.637
=-1.40

ValiRx's current Enterprise Value is £3.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ValiRx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ValiRx's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0345/-0.025
=At Loss

ValiRx's share price for today is £0.0345.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ValiRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.025.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ValiRx EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ValiRx's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.